# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate SALL4 as target

## SUMMARY OF THE INVENTION

- introduce isolated peptides
- outline therapeutic applications

## DETAILED DESCRIPTION OF THE INVENTION

### Isolated Peptides and Compositions Comprising Isolated Peptides

- define peptide
- introduce formula (I) for isolated peptides
- explain amino acid notation and conventions
- describe properties of amino acids X1-X7
- provide embodiments of isolated peptides
- introduce formula (Ia) for isolated peptides
- define isolated peptides
- describe formula (Ia)
- describe formula (II)
- define "A" in formula (II)
- define "B" in formula (II)
- describe first embodiment
- describe second embodiment
- describe third embodiment
- describe fourth embodiment
- describe fifth embodiment
- describe sixth embodiment
- describe seventh embodiment
- describe eighth to tenth embodiments
- define isolated peptides
- describe terminal ends protection
- introduce cell-penetrating peptides
- describe covalent linking of peptides
- define binding affinity
- describe IC50 values
- describe KD values
- describe binding to RBBp4 protein
- describe inhibition of RBBp4 activity
- describe pharmaceutical applications
- define SALL4 and RBBp4 proteins
- describe pharmaceutical compositions
- describe formulation of pharmaceutical compositions
- describe modes of administration

### Methods of Inhibition and Treatment

- introduce SALL4 functions
- describe SALL4-induced tumorigenesis
- disclose use of isolated peptides for disrupting SALL-NuRD interaction
- describe method for inhibiting SALL4-RBBp4 interaction
- define cell types
- explain high levels of SALL4
- provide method for inhibiting SALL4-RBBp4 interaction in malignant cells
- describe method for treating disorders mediated by SALL4 dysregulation
- define pharmaceutical composition
- explain administration routes and dosage forms
- describe therapeutically effective amount
- provide method for treating cancer
- specify solid tumors that can be treated
- describe method for treating hematological cancer

### Exemplification

- demonstrate SALL4 binding to RBBp4
- determine crystal structure of RBBp4-SALL4 complex
- identify key interactions between SALL4 and RBBp4
- perform computational analysis of RBBp4-SALL4 interaction
- identify essential residues for RBBp4-SALL4 interaction
- perform cell viability assay with mutant peptide
- optimize candidate therapeutic peptide
- determine minimum length of peptide required for bioactivity
- perform systematic single-residue mutation analysis
- test therapeutic peptide FFW in vitro
- test therapeutic peptide FFW in vivo
- study therapeutic effect of PEN-FFW in HCC cells
- evaluate drug-like properties of PEN-FFW
- perform transcriptome analysis of differentially expressed genes

### Materials and Methods

- describe ITC assay
- describe SPR assay
- describe FP assay
- describe crystallization and structure determination
- describe computational alanine scanning
- describe cell culture and treatment with peptide
- describe xenograft studies
- describe toxicology study
- describe plasma stability of PEN-FFW
- describe live cell imaging and RNA-seq data analysis

